Big Bull的个人主页 - 老虎社区

Big Bull

Big Bull

暂无个人介绍

IP属地：未知

109关注

12粉丝

0主题

0勋章

2021-11-01

👍

Federal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote>

2021-12-16

Okay 👌

Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>

2021-11-22

👍

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>

2021-11-03

Okay

抱歉，原内容已删除

2021-12-05

Ok

抱歉，原内容已删除

2021-11-18

Good

Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>

2021-11-03

👌

抱歉，原内容已删除

2021-11-01

Okay

2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>

2021-11-24

👌

抱歉，原内容已删除

2021-11-10

Okay 👌

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4094912318336650","uuid":"4094912318336650","gmtCreate":1631809253633,"gmtModify":1635129709650,"name":"Big Bull","pinyin":"bigbullbigbull","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":109,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.69%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":690874632,"gmtCreate":1639659855187,"gmtModify":1639659855348,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay 👌&nbsp;","listText":"Okay 👌&nbsp;","text":"Okay 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690874632","repostId":"1142996286","repostType":4,"repost":{"id":"1142996286","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639659703,"share":"https://www.laohu8.com/m/news/1142996286?lang=zh_CN&edition=full","pubTime":"2021-12-16 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142996286","media":"Tiger Newspress","summary":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.$Delta Air Lines$ – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-","content":"<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p><p><blockquote>美国股指期货周四上午上涨，此前市场在前一交易日出现180度大转弯，欢迎美联储决定加快缩减规模并暂时维持利率不变。</blockquote></p><p> At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨204点，涨幅0.57%，标普500 e-mini上涨31.25点，涨幅0.66%，纳斯达克100 e-mini上涨115.25点，涨幅0.71%。随着美联储周三给市场喘息的机会，交易员将在周四转向劳工部关于每周首次申请失业救济人数的最新数据。首次申请失业救济人数预计将在去年创下52周低点后小幅上升。</blockquote></p><p> <b>Stocks making the biggest moves premarket: </b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p><p><blockquote><b><a href=\"https://laohu8.com/S/DAL\">达美航空</a></b>-达美航空预计第四季度利润为2亿美元，盘前上涨2.3%。市场普遍预测达美航空将出现季度亏损，但该航空公司表示，假期需求强劲，利润有望超过大流行前的水平。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ACN\">埃森哲公司</a></b>-该咨询公司公布最新季度利润和收入好于预期，并上调2022财年盈利指引后，其股价盘前飙升6.7%。埃森哲客户群中四个最大行业集团的收入增长了20%以上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p><p><blockquote><b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>-该制药商表示其抗体鸡尾酒对奥密克戎Covid-19变种失去效力后，其股价在盘前交易中下跌1%。再生元确实说过这种鸡尾酒对德尔塔变异毒株有效。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p><p><blockquote><b><a href=\"https://laohu8.com/S/LEN\">伦纳尔</a></b>-Lennar公布的季度收益为每股3.91美元，低于市场普遍预期的4.15美元，该住宅建筑商的收入也低于预期。Lennar受到木材成本上涨、劳动力成本增加和原材料短缺的影响，导致送货上门延迟。Lennar在盘前下跌6.3%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/NVS\">诺华公司</a></b>-诺华启动了一项价值高达150亿美元的新股票回购计划，该制药商计划在2023年底前完成这些回购。股价在盘前交易中上涨4%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p><p><blockquote><b><a href=\"https://laohu8.com/S/V\">签证</a> </b>–<a href=\"https://laohu8.com/S/V\">签证</a>盘前股价上涨1.1%，此前该公司宣布向其股票回购计划增加120亿美元，使其回购授权总额达到132亿美元。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SJM\">Smucker的</a></b>-Smucker达成协议，以1.1亿美元的价格将其天然饮料和谷物业务出售给私募股权公司Nexus Capital Management，这家食品生产商表示希望将更多资源集中在其核心品牌上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ISRG\">直观手术</a></b>–<a href=\"https://laohu8.com/S/ISRG\">直观手术</a>被添加到高盛的“坚定买入”名单中，这表明该公司即将推出一种新的手术系统。盘前股价上涨1.2%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/T\">AT&amp;T公司</a></b>-摩根士丹利将AT&amp;T的评级从“同等权重”上调至“跑赢大盘”，称该股近期的下滑创造了有吸引力的风险回报状况。该公司表示，还有其他几个关键因素推动了此次升级，包括WarnerMedia/Discovery合并即将完成。AT&amp;T在盘前交易中上涨1.5%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p><p><blockquote><b><a href=\"https://laohu8.com/S/WOOF\">Petco健康和保健公司。</a></b>-在Needham开始给予“买入”评级后，这家宠物产品销售商的股价在盘前上涨了1.9%。该公司认为，鉴于Petco在包括兽医医院在内的多个渠道中的存在，它应该会超越宠物类别的竞争对手。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>–Evercore将其评级从“持平”上调至“跑赢大盘”后，该电子商务平台运营商在盘前交易中上涨2.9%。Evercore指出，该股比年度高点低约20%，就增长机会而言，该公司代表着优质资产。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-16 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p><p><blockquote>美国股指期货周四上午上涨，此前市场在前一交易日出现180度大转弯，欢迎美联储决定加快缩减规模并暂时维持利率不变。</blockquote></p><p> At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨204点，涨幅0.57%，标普500 e-mini上涨31.25点，涨幅0.66%，纳斯达克100 e-mini上涨115.25点，涨幅0.71%。随着美联储周三给市场喘息的机会，交易员将在周四转向劳工部关于每周首次申请失业救济人数的最新数据。首次申请失业救济人数预计将在去年创下52周低点后小幅上升。</blockquote></p><p> <b>Stocks making the biggest moves premarket: </b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p><p><blockquote><b><a href=\"https://laohu8.com/S/DAL\">达美航空</a></b>-达美航空预计第四季度利润为2亿美元，盘前上涨2.3%。市场普遍预测达美航空将出现季度亏损，但该航空公司表示，假期需求强劲，利润有望超过大流行前的水平。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ACN\">埃森哲公司</a></b>-该咨询公司公布最新季度利润和收入好于预期，并上调2022财年盈利指引后，其股价盘前飙升6.7%。埃森哲客户群中四个最大行业集团的收入增长了20%以上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p><p><blockquote><b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>-该制药商表示其抗体鸡尾酒对奥密克戎Covid-19变种失去效力后，其股价在盘前交易中下跌1%。再生元确实说过这种鸡尾酒对德尔塔变异毒株有效。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p><p><blockquote><b><a href=\"https://laohu8.com/S/LEN\">伦纳尔</a></b>-Lennar公布的季度收益为每股3.91美元，低于市场普遍预期的4.15美元，该住宅建筑商的收入也低于预期。Lennar受到木材成本上涨、劳动力成本增加和原材料短缺的影响，导致送货上门延迟。Lennar在盘前下跌6.3%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/NVS\">诺华公司</a></b>-诺华启动了一项价值高达150亿美元的新股票回购计划，该制药商计划在2023年底前完成这些回购。股价在盘前交易中上涨4%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p><p><blockquote><b><a href=\"https://laohu8.com/S/V\">签证</a> </b>–<a href=\"https://laohu8.com/S/V\">签证</a>盘前股价上涨1.1%，此前该公司宣布向其股票回购计划增加120亿美元，使其回购授权总额达到132亿美元。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SJM\">Smucker的</a></b>-Smucker达成协议，以1.1亿美元的价格将其天然饮料和谷物业务出售给私募股权公司Nexus Capital Management，这家食品生产商表示希望将更多资源集中在其核心品牌上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ISRG\">直观手术</a></b>–<a href=\"https://laohu8.com/S/ISRG\">直观手术</a>被添加到高盛的“坚定买入”名单中，这表明该公司即将推出一种新的手术系统。盘前股价上涨1.2%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/T\">AT&amp;T公司</a></b>-摩根士丹利将AT&amp;T的评级从“同等权重”上调至“跑赢大盘”，称该股近期的下滑创造了有吸引力的风险回报状况。该公司表示，还有其他几个关键因素推动了此次升级，包括WarnerMedia/Discovery合并即将完成。AT&amp;T在盘前交易中上涨1.5%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p><p><blockquote><b><a href=\"https://laohu8.com/S/WOOF\">Petco健康和保健公司。</a></b>-在Needham开始给予“买入”评级后，这家宠物产品销售商的股价在盘前上涨了1.9%。该公司认为，鉴于Petco在包括兽医医院在内的多个渠道中的存在，它应该会超越宠物类别的竞争对手。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>–Evercore将其评级从“持平”上调至“跑赢大盘”后，该电子商务平台运营商在盘前交易中上涨2.9%。Evercore指出，该股比年度高点低约20%，就增长机会而言，该公司代表着优质资产。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142996286","content_text":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.\nAt 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.With the Fed giving markets a breather Wednesday, traders will turn their Thursday to fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after last’s 52-week low.\nStocks making the biggest moves premarket: \nDelta Air Lines – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.\nAccenture PLC – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.\nRegeneron Pharmaceuticals – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.\nLennar – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.\nNovartis AG – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.\nVisa – Visa rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.\nSmucker's – Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.\nIntuitive Surgical – Intuitive Surgical was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.\nAT&T Inc – Morgan Stanley upgraded AT&T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&T gained 1.5% in premarket trading.\nPetco Health and Wellness Company, Inc. – The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.\nShopify – The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":4502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608178636,"gmtCreate":1638672598165,"gmtModify":1638672598165,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608178636","repostId":"2188057871","repostType":4,"isVote":1,"tweetType":1,"viewCount":3327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874953784,"gmtCreate":1637722659359,"gmtModify":1637722659423,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874953784","repostId":"1178572049","repostType":4,"isVote":1,"tweetType":1,"viewCount":3823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874925356,"gmtCreate":1637722096502,"gmtModify":1637722118342,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874925356","repostId":"1178572049","repostType":2,"isVote":1,"tweetType":1,"viewCount":4006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875223948,"gmtCreate":1637659536449,"gmtModify":1637659536541,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875223948","repostId":"1170981862","repostType":4,"isVote":1,"tweetType":1,"viewCount":3835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875229796,"gmtCreate":1637659508214,"gmtModify":1637659508214,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay 👌&nbsp;","listText":"Okay 👌&nbsp;","text":"Okay 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875229796","repostId":"2185638587","repostType":4,"repost":{"id":"2185638587","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637659145,"share":"https://www.laohu8.com/m/news/2185638587?lang=zh_CN&edition=full","pubTime":"2021-11-23 17:19","market":"us","language":"en","title":"5 Stocks To Watch For November 23, 2021<blockquote>2021年11月23日值得关注的5只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2185638587","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\tWall Street expects  Best Buy Co Inc  (NYSE: BBY) to report quarterly earnings at $1.91 per share on revenue of $11.56 billion before the opening bell. Best Buy shares rose 0.7% to $139.00 in after-hours trading.\n","content":"<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括：</blockquote></p><p> <ul>  <li>Wall Street expects <b> Best Buy Co Inc </b> (NYSE:BBY) to report quarterly earnings at $1.91 per share on revenue of $11.56 billion before the opening bell. Best Buy shares rose 0.7% to $139.00 in after-hours trading.</li>  <li><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications Inc </b> (NASDAQ:ZM) reported better-than-expected results for its third quarter on Monday. The company reported its customers that contribute more than $100,000 in the trailing 12 months totaled 2,507, up 94% year-over-year. Zoom Video shares, however, dropped 6.8% to $225.80 in the after-hours trading session.</li>  <li>Analysts are expecting <b> <a href=\"https://laohu8.com/S/DLTR\">Dollar Tree, Inc.</a> </b> (NASDAQ:DLTR) to have earned $0.96 per share on revenue of $6.41 billion in the recent quarter. The company will release earnings before the markets open. Dollar Tree shares fell 0.7% to $131.70 in after-hours trading.</li> </ul> <ul>  <li><b><a href=\"https://laohu8.com/S/URBN\">Urban Outfitters</a>, Inc.</b> (NASDAQ:URBN) posted upbeat earnings and sales results for the third quarter. Its same-store sales climbed 14.6% year-over-year during the quarter. Urban Outfitters shares tumbled 12.1% to $32.78 in the after-hours trading session.</li>  <li>Analysts expect <b> HP Inc </b> (NYSE:HPQ) to post quarterly earnings at $0.88 per share on revenue of $15.40 billion after the closing bell. HP shares rose 0.2% to $32.00 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>百思买公司</b>（纽约证券交易所股票代码：BBY）将在开盘前公布季度收益为每股1.91美元，营收为115.6亿美元。百思买股价在盘后交易中上涨0.7%，至139.00美元。</li><li><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信公司</b>（纳斯达克：ZM）周一公布了好于预期的第三季度业绩。该公司报告称，过去12个月捐款超过10万美元的客户总数为2,507人，同比增长94%。然而，Zoom Video股价在盘后交易时段下跌6.8%，至225.80美元。</li><li>分析师预计<b><a href=\"https://laohu8.com/S/DLTR\">美元树公司。</a></b>（纳斯达克股票代码：DLTR）最近一个季度每股收益0.96美元，营收为64.1亿美元。该公司将在开市前发布财报。Dollar Tree股价在盘后交易中下跌0.7%，至131.70美元。</li></ul><ul><li><b><a href=\"https://laohu8.com/S/URBN\">城市服装店</a>，公司。</b>（纳斯达克：URBN）公布了乐观的第三季度盈利和销售业绩。本季度同店销售额同比增长14.6%。Urban Outfitters股价在盘后交易时段下跌12.1%，至32.78美元。</li><li>分析师预计<b>惠普公司</b>（纽约证券交易所股票代码：HPQ）收盘后公布季度收益为每股0.88美元，营收为154亿美元。惠普股价在盘后交易中上涨0.2%，至32.00美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 23, 2021<blockquote>2021年11月23日值得关注的5只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 23, 2021<blockquote>2021年11月23日值得关注的5只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-11-23 17:19</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括：</blockquote></p><p> <ul>  <li>Wall Street expects <b> Best Buy Co Inc </b> (NYSE:BBY) to report quarterly earnings at $1.91 per share on revenue of $11.56 billion before the opening bell. Best Buy shares rose 0.7% to $139.00 in after-hours trading.</li>  <li><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications Inc </b> (NASDAQ:ZM) reported better-than-expected results for its third quarter on Monday. The company reported its customers that contribute more than $100,000 in the trailing 12 months totaled 2,507, up 94% year-over-year. Zoom Video shares, however, dropped 6.8% to $225.80 in the after-hours trading session.</li>  <li>Analysts are expecting <b> <a href=\"https://laohu8.com/S/DLTR\">Dollar Tree, Inc.</a> </b> (NASDAQ:DLTR) to have earned $0.96 per share on revenue of $6.41 billion in the recent quarter. The company will release earnings before the markets open. Dollar Tree shares fell 0.7% to $131.70 in after-hours trading.</li> </ul> <ul>  <li><b><a href=\"https://laohu8.com/S/URBN\">Urban Outfitters</a>, Inc.</b> (NASDAQ:URBN) posted upbeat earnings and sales results for the third quarter. Its same-store sales climbed 14.6% year-over-year during the quarter. Urban Outfitters shares tumbled 12.1% to $32.78 in the after-hours trading session.</li>  <li>Analysts expect <b> HP Inc </b> (NYSE:HPQ) to post quarterly earnings at $0.88 per share on revenue of $15.40 billion after the closing bell. HP shares rose 0.2% to $32.00 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>百思买公司</b>（纽约证券交易所股票代码：BBY）将在开盘前公布季度收益为每股1.91美元，营收为115.6亿美元。百思买股价在盘后交易中上涨0.7%，至139.00美元。</li><li><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信公司</b>（纳斯达克：ZM）周一公布了好于预期的第三季度业绩。该公司报告称，过去12个月捐款超过10万美元的客户总数为2,507人，同比增长94%。然而，Zoom Video股价在盘后交易时段下跌6.8%，至225.80美元。</li><li>分析师预计<b><a href=\"https://laohu8.com/S/DLTR\">美元树公司。</a></b>（纳斯达克股票代码：DLTR）最近一个季度每股收益0.96美元，营收为64.1亿美元。该公司将在开市前发布财报。Dollar Tree股价在盘后交易中下跌0.7%，至131.70美元。</li></ul><ul><li><b><a href=\"https://laohu8.com/S/URBN\">城市服装店</a>，公司。</b>（纳斯达克：URBN）公布了乐观的第三季度盈利和销售业绩。本季度同店销售额同比增长14.6%。Urban Outfitters股价在盘后交易时段下跌12.1%，至32.78美元。</li><li>分析师预计<b>惠普公司</b>（纽约证券交易所股票代码：HPQ）收盘后公布季度收益为每股0.88美元，营收为154亿美元。惠普股价在盘后交易中上涨0.2%，至32.00美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","URBN":"都市服饰","DLTR":"美元树公司","BK4548":"巴美列捷福持仓","BK4170":"电脑硬件、储存设备及电脑周边","BK4094":"服装零售","BK4551":"寇图资本持仓","BK4525":"远程办公概念","ZM":"Zoom","BK4023":"应用软件","BK4114":"综合货品商店","BBY":"百思买","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4567":"ESG概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4076":"电脑与电子产品零售","BK4528":"SaaS概念","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185638587","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects  Best Buy Co Inc  (NYSE:BBY) to report quarterly earnings at $1.91 per share on revenue of $11.56 billion before the opening bell. Best Buy shares rose 0.7% to $139.00 in after-hours trading.\nZoom Video Communications Inc  (NASDAQ:ZM) reported better-than-expected results for its third quarter on Monday. The company reported its customers that contribute more than $100,000 in the trailing 12 months totaled 2,507, up 94% year-over-year. Zoom Video shares, however, dropped 6.8% to $225.80 in the after-hours trading session.\nAnalysts are expecting  Dollar Tree, Inc.  (NASDAQ:DLTR) to have earned $0.96 per share on revenue of $6.41 billion in the recent quarter. The company will release earnings before the markets open. Dollar Tree shares fell 0.7% to $131.70 in after-hours trading.\n\n\nUrban Outfitters, Inc. (NASDAQ:URBN) posted upbeat earnings and sales results for the third quarter. Its same-store sales climbed 14.6% year-over-year during the quarter. Urban Outfitters shares tumbled 12.1% to $32.78 in the after-hours trading session.\nAnalysts expect  HP Inc  (NYSE:HPQ) to post quarterly earnings at $0.88 per share on revenue of $15.40 billion after the closing bell. HP shares rose 0.2% to $32.00 in after-hours trading.","news_type":1,"symbols_score_info":{"ZM":0.9,"DLTR":0.9,"URBN":0.9,"BBY":0.9}},"isVote":1,"tweetType":1,"viewCount":3329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872777574,"gmtCreate":1637582901485,"gmtModify":1637582901485,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872777574","repostId":"1171692239","repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-22 20:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09888":"百度集团-SW","SNYNF":"Sanofi","BIDU":"百度"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"SNYNF":0.9,"09888":0.9,"BIDU":0.9}},"isVote":1,"tweetType":1,"viewCount":9300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872777162,"gmtCreate":1637582785582,"gmtModify":1637582785582,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872777162","repostId":"1156227996","repostType":4,"repost":{"id":"1156227996","kind":"news","pubTimestamp":1637574816,"share":"https://www.laohu8.com/m/news/1156227996?lang=zh_CN&edition=full","pubTime":"2021-11-22 17:53","market":"us","language":"en","title":"Ford's 160,000 Reservations Number For F-150 Lightning Doesn't Include Fleet Orders<blockquote>福特F-150 Lightning的160,000份预订量不包括车队订单</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156227996","media":"Benzinga","summary":"Ford Motor Co’s highly-anticipated electric truck F-150 Lightning has 160,000 bookings but those ord","content":"<p><div> Ford Motor Co’s highly-anticipated electric truck F-150 Lightning has 160,000 bookings but those orders don't include fleet buyers, the company told Electrek. What Happened:The base model of the Ford’...</p><p><blockquote><div>福特汽车公司告诉Electrek，备受期待的电动卡车F-150 Lightning已收到16万份预订，但这些订单不包括车队买家。发生了什么：福特的基本型号...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford's 160,000 Reservations Number For F-150 Lightning Doesn't Include Fleet Orders<blockquote>福特F-150 Lightning的160,000份预订量不包括车队订单</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord's 160,000 Reservations Number For F-150 Lightning Doesn't Include Fleet Orders<blockquote>福特F-150 Lightning的160,000份预订量不包括车队订单</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-11-22 17:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Ford Motor Co’s highly-anticipated electric truck F-150 Lightning has 160,000 bookings but those orders don't include fleet buyers, the company told Electrek. What Happened:The base model of the Ford’...</p><p><blockquote><div>福特汽车公司告诉Electrek，备受期待的电动卡车F-150 Lightning已收到16万份预订，但这些订单不包括车队买家。发生了什么：福特的基本型号...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"source_url":"https://www.benzinga.com/news/21/11/24214595/fords-160-000-reservations-number-for-f-150-lightning-doesnt-include-fleet-orders","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156227996","content_text":"Ford Motor Co’s highly-anticipated electric truck F-150 Lightning has 160,000 bookings but those orders don't include fleet buyers, the company told Electrek.\nWhat Happened:The base model of the Ford’s F-150 Lightning is expected to draw more commercial and fleet customers than the more expensive variants.\nThe revelation means that customers are likely looking at longer wait times than previously anticipated, Electrek noted.\nThe electric version of Ford’s most profitable and popular pickup truck would will go on sale in May at a ticket price of $39,974 and up for the base model and a range of 230 miles for the standard range.\nFor perspective, the F-150 alone contributed over 27% of Ford’s total production numbers of 201,353 units in the month of October, as per the company data.\nThe Dearborn, Michigan-based automaker is aiming to ramp up production for the F-150 Lightning electric truck and build 15,000 F-150s next year after the truck's spring launch, 55,000 in 2023 and eventually reach the 80,000 mark in 2024.\nWhy It Matters:Ford is expecting the popularity of its most-sold and the most-profitable full size pickup truck F-150 to trickle down to its electric variant as well.\nFord CEO Jim Farley last week said the automaker will double electric vehicle production to 600,000 units by 2023 due to higher demand and said it aims the automaker to become the biggest electric vehicle maker in the world.\nFarley in May this year told investors the automaker plans to electrify its most iconic models and reconfirmed the plans to launch a commercial self-driving business by 2022.\nF-150 Lightning will be Ford’s second fully electric model on sale after Mustang Mach-E.\nPrice Action:Ford stock closed 0.87% lower at $19.39 a share on Friday.","news_type":1,"symbols_score_info":{"F":0.9}},"isVote":1,"tweetType":1,"viewCount":4254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876204588,"gmtCreate":1637314320200,"gmtModify":1637314320356,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Is time to fly up to the moon Ali!&nbsp;[看涨]&nbsp;","listText":"Is time to fly up to the moon Ali!&nbsp;[看涨]&nbsp;","text":"Is time to fly up to the moon Ali! [看涨]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876204588","repostId":"876205840","repostType":1,"repost":{"id":876205840,"gmtCreate":1637314097576,"gmtModify":1637378903861,"author":{"id":"212008496769156","authorId":"212008496769156","name":"捷克Jack","avatar":"https://static.tigerbbs.com/7cc48e563d37c21562541a2874ce20e4","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"212008496769156","authorIdStr":"212008496769156"},"themes":[],"title":"财报季专供：中概风险，从权利金里赚回来吧","htmlText":"今天的主角是<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 财报后大跌11%，可能还要跌。 原因很简单： 收入不及预期 利润不及预期 指引还下调了 唯一还不错的是云业务的发展不错以及海外活跃用户的增长。但中国人往往喜欢“丑话说在前面”，当这一季表现得这么糟糕的时候，往往就有可能是为了以后在做铺垫，因此很多人也在考虑要不要抄底。 财报季我做了很多“财报前期权策略”，本质上还是在意财报这种公司事件带来的波动性。的确，很多人谈“波动色变”，但是我觉得，波动也同时给我们带啦机会。 对期权玩家来说，波动——Volatility是最重要的数据指标之一。简单地说，当波动率越大的时候，相同情况产生的权利金就越高，这样对期权的概念而 今天的策略很简单，naked&nbsp;sell&nbsp;put 可能很多朋友都用惯了这个策略，我想再强调一些概念。 首先，Long和Short，分别代表“多方”和“空方”，代表你是看涨还是看跌。 然后，Buy和Sell，分别代表“买”和“卖”的动作，代表你对标的产品的交易动作。 那么，有Buy操作的一定是“多方”，有Sell操作的一定是“空方”对吗？ 显然不是。 因为期权分为“看涨期权Call”和“看跌期权Put”—— 当我们“Buy&nbsp;Put”，也就买入看跌期权的时候，我们就是“Short空方”，和我们“Sell&nbsp;Call”也就是卖出看涨期权的时候一样，都是“Short空方”； 反之，当我们“Buy&nbsp;Call”买入看涨期权的时候，我们就是“Long多方”，和我们“Sell&nbsp;","listText":"今天的主角是<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 财报后大跌11%，可能还要跌。 原因很简单： 收入不及预期 利润不及预期 指引还下调了 唯一还不错的是云业务的发展不错以及海外活跃用户的增长。但中国人往往喜欢“丑话说在前面”，当这一季表现得这么糟糕的时候，往往就有可能是为了以后在做铺垫，因此很多人也在考虑要不要抄底。 财报季我做了很多“财报前期权策略”，本质上还是在意财报这种公司事件带来的波动性。的确，很多人谈“波动色变”，但是我觉得，波动也同时给我们带啦机会。 对期权玩家来说，波动——Volatility是最重要的数据指标之一。简单地说，当波动率越大的时候，相同情况产生的权利金就越高，这样对期权的概念而 今天的策略很简单，naked&nbsp;sell&nbsp;put 可能很多朋友都用惯了这个策略，我想再强调一些概念。 首先，Long和Short，分别代表“多方”和“空方”，代表你是看涨还是看跌。 然后，Buy和Sell，分别代表“买”和“卖”的动作，代表你对标的产品的交易动作。 那么，有Buy操作的一定是“多方”，有Sell操作的一定是“空方”对吗？ 显然不是。 因为期权分为“看涨期权Call”和“看跌期权Put”—— 当我们“Buy&nbsp;Put”，也就买入看跌期权的时候，我们就是“Short空方”，和我们“Sell&nbsp;Call”也就是卖出看涨期权的时候一样，都是“Short空方”； 反之，当我们“Buy&nbsp;Call”买入看涨期权的时候，我们就是“Long多方”，和我们“Sell&nbsp;","text":"今天的主角是$阿里巴巴(BABA)$ $阿里巴巴-SW(09988)$ 财报后大跌11%，可能还要跌。 原因很简单： 收入不及预期 利润不及预期 指引还下调了 唯一还不错的是云业务的发展不错以及海外活跃用户的增长。但中国人往往喜欢“丑话说在前面”，当这一季表现得这么糟糕的时候，往往就有可能是为了以后在做铺垫，因此很多人也在考虑要不要抄底。 财报季我做了很多“财报前期权策略”，本质上还是在意财报这种公司事件带来的波动性。的确，很多人谈“波动色变”，但是我觉得，波动也同时给我们带啦机会。 对期权玩家来说，波动——Volatility是最重要的数据指标之一。简单地说，当波动率越大的时候，相同情况产生的权利金就越高，这样对期权的概念而 今天的策略很简单，naked sell put 可能很多朋友都用惯了这个策略，我想再强调一些概念。 首先，Long和Short，分别代表“多方”和“空方”，代表你是看涨还是看跌。 然后，Buy和Sell，分别代表“买”和“卖”的动作，代表你对标的产品的交易动作。 那么，有Buy操作的一定是“多方”，有Sell操作的一定是“空方”对吗？ 显然不是。 因为期权分为“看涨期权Call”和“看跌期权Put”—— 当我们“Buy Put”，也就买入看跌期权的时候，我们就是“Short空方”，和我们“Sell Call”也就是卖出看涨期权的时候一样，都是“Short空方”； 反之，当我们“Buy Call”买入看涨期权的时候，我们就是“Long多方”，和我们“Sell","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876205840","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878532818,"gmtCreate":1637204855941,"gmtModify":1637204855941,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878532818","repostId":"1163438397","repostType":4,"repost":{"id":"1163438397","kind":"news","pubTimestamp":1637202293,"share":"https://www.laohu8.com/m/news/1163438397?lang=zh_CN&edition=full","pubTime":"2021-11-18 10:24","market":"us","language":"en","title":"Bitcoin Needs to Drop 80% Before Marathon Loses Money on Mining<blockquote>比特币需要股价下跌80%才能让马拉松矿业亏损</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163438397","media":"Bloomberg","summary":"(Bloomberg) -- Bitcoin has a long way to drop before mining the digital token becomes unprofitable f","content":"<p>(Bloomberg) -- Bitcoin has a long way to drop before mining the digital token becomes unprofitable for North America’s largest crypto mining company.</p><p><blockquote>（彭博社）——对于北美最大的加密货币挖矿公司来说，在开采数字代币变得无利可图之前，比特币还有很长的路要走。</blockquote></p><p> After factoring in energy and hosting costs, the breakeven rate on Bitcoin for Marathon Digital Holdings Inc. is roughly $6,500, according to Fred Thiel, the Las Vegas-based company’s chief executive officer. Even with this week’s drop from an all-time high of $68,991 to around $60,000, the world’s largest cryptocurrency would need to plunge 80% before hitting the breakeven level.</p><p><blockquote>Marathon Digital Holdings Inc.首席执行官Fred Thiel表示，考虑到能源和托管成本后，该公司在比特币的盈亏平衡率约为6,500美元。即使本周从68,991美元的历史高点跌至60,000美元左右，全球最大的加密货币也需要暴跌80%才能达到盈亏平衡水平。</blockquote></p><p> “It’s obviously a very profitable business,” Thiel said on Bloomberg’s “QuickTake Stock” streaming program. “We can ride this market for quite a long time. Bitcoin would have to drop obviously 80% before it starts getting to be a challenging situation for us, so we’re quite comfortable with where our costs are today.”</p><p><blockquote>“这显然是一项非常有利可图的业务，”泰尔在彭博社的“QuickTake Stock”流媒体节目中表示。“我们可以在这个市场上占据很长一段时间。比特币必须明显下降80%，然后才能开始对我们构成挑战，因此我们对目前的成本状况感到非常满意。”</blockquote></p><p> The breakeven estimate serves as a reminder on how profitable Bitcoin mining can be for larger-scale companies and helps to explain the almost fivefold increase in Marathon’s share price this year.</p><p><blockquote>盈亏平衡估计提醒人们比特币采矿业对于大型公司来说的盈利能力如何，并有助于解释今年马拉松股价上涨近五倍的原因。</blockquote></p><p> Daily miner revenue is hovering near record highs, according to data compiled by crypto derivatives provider FRNT Financial Inc. Marathon has among the lowest mining costs per coin, DA Davidson analyst Chris Brendler -- who has a buy rating on the shares -- told Bloomberg. Miners earn new Bitcoin by solving complex mathematical equations that secure the blockchain network while processing transactions.</p><p><blockquote>根据加密衍生品提供商FRNT Financial Inc.编制的数据，每日矿商收入徘徊在历史新高附近。DA Davidson分析师克里斯·布伦德勒(Chris Brendler)对该股给予买入评级，他告诉彭博社。矿工通过解决复杂的数学方程来赚取新的比特币，这些方程在处理交易时保护区块链网络。</blockquote></p><p> Marathon’s shares plunged about 33% this week after a quarterly filing showed that the company received a subpoena from the U.S. Securities and Exchange Commission related to a partnership for a Montana data facility. Thiel declined to comment further on the probe.</p><p><blockquote>马拉松的股价本周暴跌约33%，此前一份季度文件显示，该公司收到了美国证券交易委员会关于蒙大拿州数据设施合作的传票。泰尔拒绝就调查进一步置评。</blockquote></p><p> The company is planning upgrades to operations, with 130,000 previously purchased machines expected to go live from now to mid-2022. At the end of the third quarter, Marathon raised their hash rate, or their computational power, to 2.7 exahashes per second and generated 1,252 self-mined coins -- a 91% jump from second-quarter production; it held roughly 7,053 Bitcoin by quarter-end.</p><p><blockquote>该公司正在计划升级运营，预计从现在到2022年中期，之前购买的13万台机器将投入使用。第三季度末，Marathon将其哈希率（即计算能力）提高到每秒2.7 exahashes，并生成了1,252枚自挖代币，比第二季度产量增长了91%；截至季度末，该公司拥有约7,053个比特币。</blockquote></p><p> Marathon tapped the debt markets this week to sell convertible bonds -- an offering that was increased to $650 million. The proceeds will be used to upgrade mining equipment and potentially fund acquisitions, Thiel said.</p><p><blockquote>马拉松本周利用债务市场出售可转换债券，发行规模增至6.5亿美元。泰尔表示，所得款项将用于升级采矿设备并可能为收购提供资金。</blockquote></p><p> “Having cash on the balance sheet allows us to take advantage of opportunities to buy more miners, or we could potentially acquire miner companies, we could invest in technologies that could dramatically lower or improve the energy efficiency of our mining operations,” Thiel said. “We want to be agile, we want to have optionality.”</p><p><blockquote>蒂尔说：“资产负债表上有现金使我们能够利用机会购买更多矿商，或者我们可能会收购矿业公司，我们可以投资于可以大幅降低或提高采矿业务能源效率的技术。”“我们想要敏捷，我们想要有选择性。”</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin Needs to Drop 80% Before Marathon Loses Money on Mining<blockquote>比特币需要股价下跌80%才能让马拉松矿业亏损</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin Needs to Drop 80% Before Marathon Loses Money on Mining<blockquote>比特币需要股价下跌80%才能让马拉松矿业亏损</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-18 10:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Bitcoin has a long way to drop before mining the digital token becomes unprofitable for North America’s largest crypto mining company.</p><p><blockquote>（彭博社）——对于北美最大的加密货币挖矿公司来说，在开采数字代币变得无利可图之前，比特币还有很长的路要走。</blockquote></p><p> After factoring in energy and hosting costs, the breakeven rate on Bitcoin for Marathon Digital Holdings Inc. is roughly $6,500, according to Fred Thiel, the Las Vegas-based company’s chief executive officer. Even with this week’s drop from an all-time high of $68,991 to around $60,000, the world’s largest cryptocurrency would need to plunge 80% before hitting the breakeven level.</p><p><blockquote>Marathon Digital Holdings Inc.首席执行官Fred Thiel表示，考虑到能源和托管成本后，该公司在比特币的盈亏平衡率约为6,500美元。即使本周从68,991美元的历史高点跌至60,000美元左右，全球最大的加密货币也需要暴跌80%才能达到盈亏平衡水平。</blockquote></p><p> “It’s obviously a very profitable business,” Thiel said on Bloomberg’s “QuickTake Stock” streaming program. “We can ride this market for quite a long time. Bitcoin would have to drop obviously 80% before it starts getting to be a challenging situation for us, so we’re quite comfortable with where our costs are today.”</p><p><blockquote>“这显然是一项非常有利可图的业务，”泰尔在彭博社的“QuickTake Stock”流媒体节目中表示。“我们可以在这个市场上占据很长一段时间。比特币必须明显下降80%，然后才能开始对我们构成挑战，因此我们对目前的成本状况感到非常满意。”</blockquote></p><p> The breakeven estimate serves as a reminder on how profitable Bitcoin mining can be for larger-scale companies and helps to explain the almost fivefold increase in Marathon’s share price this year.</p><p><blockquote>盈亏平衡估计提醒人们比特币采矿业对于大型公司来说的盈利能力如何，并有助于解释今年马拉松股价上涨近五倍的原因。</blockquote></p><p> Daily miner revenue is hovering near record highs, according to data compiled by crypto derivatives provider FRNT Financial Inc. Marathon has among the lowest mining costs per coin, DA Davidson analyst Chris Brendler -- who has a buy rating on the shares -- told Bloomberg. Miners earn new Bitcoin by solving complex mathematical equations that secure the blockchain network while processing transactions.</p><p><blockquote>根据加密衍生品提供商FRNT Financial Inc.编制的数据，每日矿商收入徘徊在历史新高附近。DA Davidson分析师克里斯·布伦德勒(Chris Brendler)对该股给予买入评级，他告诉彭博社。矿工通过解决复杂的数学方程来赚取新的比特币，这些方程在处理交易时保护区块链网络。</blockquote></p><p> Marathon’s shares plunged about 33% this week after a quarterly filing showed that the company received a subpoena from the U.S. Securities and Exchange Commission related to a partnership for a Montana data facility. Thiel declined to comment further on the probe.</p><p><blockquote>马拉松的股价本周暴跌约33%，此前一份季度文件显示，该公司收到了美国证券交易委员会关于蒙大拿州数据设施合作的传票。泰尔拒绝就调查进一步置评。</blockquote></p><p> The company is planning upgrades to operations, with 130,000 previously purchased machines expected to go live from now to mid-2022. At the end of the third quarter, Marathon raised their hash rate, or their computational power, to 2.7 exahashes per second and generated 1,252 self-mined coins -- a 91% jump from second-quarter production; it held roughly 7,053 Bitcoin by quarter-end.</p><p><blockquote>该公司正在计划升级运营，预计从现在到2022年中期，之前购买的13万台机器将投入使用。第三季度末，Marathon将其哈希率（即计算能力）提高到每秒2.7 exahashes，并生成了1,252枚自挖代币，比第二季度产量增长了91%；截至季度末，该公司拥有约7,053个比特币。</blockquote></p><p> Marathon tapped the debt markets this week to sell convertible bonds -- an offering that was increased to $650 million. The proceeds will be used to upgrade mining equipment and potentially fund acquisitions, Thiel said.</p><p><blockquote>马拉松本周利用债务市场出售可转换债券，发行规模增至6.5亿美元。泰尔表示，所得款项将用于升级采矿设备并可能为收购提供资金。</blockquote></p><p> “Having cash on the balance sheet allows us to take advantage of opportunities to buy more miners, or we could potentially acquire miner companies, we could invest in technologies that could dramatically lower or improve the energy efficiency of our mining operations,” Thiel said. “We want to be agile, we want to have optionality.”</p><p><blockquote>蒂尔说：“资产负债表上有现金使我们能够利用机会购买更多矿商，或者我们可能会收购矿业公司，我们可以投资于可以大幅降低或提高采矿业务能源效率的技术。”“我们想要敏捷，我们想要有选择性。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/bitcoin-needs-drop-80-marathon-211542806.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MARA":"MARA Holdings"},"source_url":"https://finance.yahoo.com/news/bitcoin-needs-drop-80-marathon-211542806.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163438397","content_text":"(Bloomberg) -- Bitcoin has a long way to drop before mining the digital token becomes unprofitable for North America’s largest crypto mining company.\nAfter factoring in energy and hosting costs, the breakeven rate on Bitcoin for Marathon Digital Holdings Inc. is roughly $6,500, according to Fred Thiel, the Las Vegas-based company’s chief executive officer. Even with this week’s drop from an all-time high of $68,991 to around $60,000, the world’s largest cryptocurrency would need to plunge 80% before hitting the breakeven level.\n“It’s obviously a very profitable business,” Thiel said on Bloomberg’s “QuickTake Stock” streaming program. “We can ride this market for quite a long time. Bitcoin would have to drop obviously 80% before it starts getting to be a challenging situation for us, so we’re quite comfortable with where our costs are today.”\nThe breakeven estimate serves as a reminder on how profitable Bitcoin mining can be for larger-scale companies and helps to explain the almost fivefold increase in Marathon’s share price this year.\nDaily miner revenue is hovering near record highs, according to data compiled by crypto derivatives provider FRNT Financial Inc. Marathon has among the lowest mining costs per coin, DA Davidson analyst Chris Brendler -- who has a buy rating on the shares -- told Bloomberg. Miners earn new Bitcoin by solving complex mathematical equations that secure the blockchain network while processing transactions.\nMarathon’s shares plunged about 33% this week after a quarterly filing showed that the company received a subpoena from the U.S. Securities and Exchange Commission related to a partnership for a Montana data facility. Thiel declined to comment further on the probe.\nThe company is planning upgrades to operations, with 130,000 previously purchased machines expected to go live from now to mid-2022. At the end of the third quarter, Marathon raised their hash rate, or their computational power, to 2.7 exahashes per second and generated 1,252 self-mined coins -- a 91% jump from second-quarter production; it held roughly 7,053 Bitcoin by quarter-end.\nMarathon tapped the debt markets this week to sell convertible bonds -- an offering that was increased to $650 million. The proceeds will be used to upgrade mining equipment and potentially fund acquisitions, Thiel said.\n“Having cash on the balance sheet allows us to take advantage of opportunities to buy more miners, or we could potentially acquire miner companies, we could invest in technologies that could dramatically lower or improve the energy efficiency of our mining operations,” Thiel said. “We want to be agile, we want to have optionality.”","news_type":1,"symbols_score_info":{"MARA":0.9}},"isVote":1,"tweetType":1,"viewCount":2661,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878532155,"gmtCreate":1637204802922,"gmtModify":1637204802922,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878532155","repostId":"1161909759","repostType":4,"isVote":1,"tweetType":1,"viewCount":1503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878536636,"gmtCreate":1637204700313,"gmtModify":1637204700313,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878536636","repostId":"1155680084","repostType":4,"isVote":1,"tweetType":1,"viewCount":1557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847463409,"gmtCreate":1636546529729,"gmtModify":1636546529907,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay 👌&nbsp;","listText":"Okay 👌&nbsp;","text":"Okay 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847463409","repostId":"1153527139","repostType":4,"repost":{"id":"1153527139","kind":"news","pubTimestamp":1636545864,"share":"https://www.laohu8.com/m/news/1153527139?lang=zh_CN&edition=full","pubTime":"2021-11-10 20:04","market":"us","language":"en","title":"Tesla Further Extends Delivery Time For Model Y Standard Range In China<blockquote>特斯拉进一步延长Model Y标准续航在华交付时间</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1153527139","media":"Benzinga","summary":"Tesla Inc’s mid-size sports utility vehicle ModelY would now take even longer with deliveries in Chi","content":"<p><div> Tesla Inc’s mid-size sports utility vehicle ModelY would now take even longer with deliveries in China, the electric vehicle maker’s website shows. What Happened:The delivery time for the $43,200 ...</p><p><blockquote><div>电动汽车制造商特斯拉公司的网站显示，该公司的中型运动型多用途车ModelY现在在中国的交付时间将更长。发生了什么：43,200美元的交货时间...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Further Extends Delivery Time For Model Y Standard Range In China<blockquote>特斯拉进一步延长Model Y标准续航在华交付时间</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Further Extends Delivery Time For Model Y Standard Range In China<blockquote>特斯拉进一步延长Model Y标准续航在华交付时间</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-11-10 20:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Tesla Inc’s mid-size sports utility vehicle ModelY would now take even longer with deliveries in China, the electric vehicle maker’s website shows. What Happened:The delivery time for the $43,200 ...</p><p><blockquote><div>电动汽车制造商特斯拉公司的网站显示，该公司的中型运动型多用途车ModelY现在在中国的交付时间将更长。发生了什么：43,200美元的交货时间...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/news/21/11/24005848/tesla-further-extends-delivery-time-for-model-y-standard-range-in-china","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153527139","content_text":"Tesla Inc’s mid-size sports utility vehicle ModelY would now take even longer with deliveries in China, the electric vehicle maker’s website shows.\nWhat Happened:The delivery time for the $43,200 Model Y standard range is now stretched to 10-14 weeks, from the earlier 6-10 weeks range.\nThe delivery for the Long Range and the Performance variant is estimated to take place in the fourth quarter; cnEVpost first reported on the development.\nWhy It Matters:Tesla launched the locally made Model Y standard range in July and started customer deliveries on August 26. The entry-level variant of Model Y uses CATL's more affordable lithium iron phosphate batteries.\nThe Elon Musk-led company sold 54,391 electric vehicles to dealers in China in October, a rise of 348% on a year-on-year basis, as per China Passenger Car Association.\nPrice Action:Tesla shares closed 11.99% lower at $1,023.50 a share on Tuesday.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":875,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841619557,"gmtCreate":1635905743400,"gmtModify":1635905743400,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841619557","repostId":"1186977790","repostType":4,"isVote":1,"tweetType":1,"viewCount":1346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841634688,"gmtCreate":1635905542092,"gmtModify":1635905542092,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841634688","repostId":"2180736486","repostType":4,"isVote":1,"tweetType":1,"viewCount":1123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849836891,"gmtCreate":1635740774157,"gmtModify":1635740774157,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849836891","repostId":"1164035523","repostType":4,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MREO":"Mereo Biopharma Group Plc","SENS":"Senseonics Holdings,Inc."},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"MREO":0.9,"SENS":0.9}},"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849838403,"gmtCreate":1635740738541,"gmtModify":1635740738634,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849838403","repostId":"2179250221","repostType":4,"repost":{"id":"2179250221","kind":"news","pubTimestamp":1635721559,"share":"https://www.laohu8.com/m/news/2179250221?lang=zh_CN&edition=full","pubTime":"2021-11-01 07:05","market":"us","language":"en","title":"Federal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2179250221","media":"Yahoo Finance","summary":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set th","content":"<p><div> The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p><p><blockquote><div>美联储即将召开的货币政策会议将成为本周的焦点，并可能为期待已久的资产购买缩减公告奠定基础。与此同时，交易者也将...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页连接</a></blockquote></p><p></p>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-11-01 07:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p><p><blockquote><div>美联储即将召开的货币政策会议将成为本周的焦点，并可能为期待已久的资产购买缩减公告奠定基础。与此同时，交易者也将...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSR":"Corsair Gaming, Inc.","ATVI":"动视暴雪","EL":"雅诗兰黛","RL":"拉夫劳伦","CLX":"高乐氏","APO":"阿波罗全球管理",".IXIC":"NASDAQ Composite","BLMN":"Bloomin' Brands",".SPX":"S&P 500 Index","PFE":"辉瑞",".DJI":"道琼斯","UBER":"优步","COP":"康菲石油"},"source_url":"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179250221","content_text":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.\nThe Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as one major tool to support the economy during the pandemic.\nIn late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome Powell suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"\n\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote Bank of America economist Michelle Meyer in a note.\n\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.\nShe noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"\nGiven the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. Investors and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.\nWASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images\nIn September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"\nWhile the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least one hike.\n\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, Charles Schwab chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"\nOctober jobs report\nOne of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.\nEconomists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.\nStill, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.\nOne factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.\n\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.\nBut some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.\nEconomic calendar\n\nMonday: Markit U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)\nTuesday: No notable reports scheduled for release\nWednesday: MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision\nThursday: Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in Q2); Unit Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)\nFriday: Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)\n\nEarnings calendar\n\nMonday: Clorox (CLX), Avis Budget Group (CAR), ZoomInfo Technologies (ZI), Chegg Inc. (CHGG), Diamondback Energy (FANG), The Simon Property Group (SPG) after market close\nTuesday: Under Armour (UAA), Estee Lauder (EL), Ralph Lauren (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), Bloomin' Brands (BLMN), ConocoPhillips (COP), Pfizer (PFE), Groupon (GPN), Marathon Petroleum (MPC) before market open; Mondelez (MDLZ), T-Mobile (TMUS), Akamai (AKAM), Activision Blizzard (ATVI), Lyft (LYFT), Match Group (MTCH), Devon Energy (DVN), Chesapeake Energy (CHK), Coursera (COUR), Zillow Group (ZG), Amgen (AMGN) after market close\nWednesday: Humana (HUM), Discovery Inc. (DISCA), The New York Times (NYT), Norwegian Cruise Line Holdings (NCLH), Marriott International (MAR), CVS Health Corp. (CVS), Sinclair Broadcast Group (SBGI) before market open; Booking Holdings (BKNG), Qorvo (QRVO), The Allstate Corp. (ALL), MGM Resorts International (MGM), $Take-Two Interactive Software(TTWO)$ (TTWO), Electronic Arts (EA), Vimeo (VMEO), Etsy (ETSY), GoDaddy (GDDY), Marathon Oil Corp. (MRO), Roku (ROKU), Qualcomm (QCOM) after market close\nThursday: Cigna (CI), Wayfair (W), ViacomCBS (VIAC), Nikola (NKLA), Duke Energy (DUK), Citrix Systems (CTXS), Regeneron Pharmaceuticals (REGN), Hanesbrands (HBI), Moderna (MRNA), Planet Fitness (PLNT), Vulcan Material (VMC), Kellogg (K), Square (SQ), Cloudflare (NET), Occidental Petroleum (OXY), Uber Technologies (UBER), American International Group (AIG), Shake Shack (SHAK), iHeartMedia (IHRT), Novavax (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), Skyworks Solutions (SWKS), Expedia (EXPE), Rocket Cos. (RKT), Live Nation Entertainment (LYV), Airbnb (ABNB)\nFriday: Wynn Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), Goodyear Tire and Rubber (GT), Cinemark Holdings (CNK) before market open","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,"UBER":0.9,"ATVI":0.9,"CLX":0.9,"BLMN":0.9,"COP":0.9,"PFE":0.9,"APO":0.9,"EL":0.9,".IXIC":0.9,"CRSR":0.9,"RL":0.9}},"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840981654,"gmtCreate":1635575212312,"gmtModify":1635575212411,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Up Tesla&nbsp;","listText":"Up Tesla&nbsp;","text":"Up Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840981654","repostId":"2179241322","repostType":4,"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":849838403,"gmtCreate":1635740738541,"gmtModify":1635740738634,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849838403","repostId":"2179250221","repostType":4,"repost":{"id":"2179250221","kind":"news","pubTimestamp":1635721559,"share":"https://www.laohu8.com/m/news/2179250221?lang=zh_CN&edition=full","pubTime":"2021-11-01 07:05","market":"us","language":"en","title":"Federal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2179250221","media":"Yahoo Finance","summary":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set th","content":"<p><div> The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p><p><blockquote><div>美联储即将召开的货币政策会议将成为本周的焦点，并可能为期待已久的资产购买缩减公告奠定基础。与此同时，交易者也将...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页连接</a></blockquote></p><p></p>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Reserve decision, October jobs report: What to know this week<blockquote>美联储决定、十月就业报告：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-11-01 07:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p><p><blockquote><div>美联储即将召开的货币政策会议将成为本周的焦点，并可能为期待已久的资产购买缩减公告奠定基础。与此同时，交易者也将...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSR":"Corsair Gaming, Inc.","ATVI":"动视暴雪","EL":"雅诗兰黛","RL":"拉夫劳伦","CLX":"高乐氏","APO":"阿波罗全球管理",".IXIC":"NASDAQ Composite","BLMN":"Bloomin' Brands",".SPX":"S&P 500 Index","PFE":"辉瑞",".DJI":"道琼斯","UBER":"优步","COP":"康菲石油"},"source_url":"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179250221","content_text":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.\nThe Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as one major tool to support the economy during the pandemic.\nIn late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome Powell suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"\n\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote Bank of America economist Michelle Meyer in a note.\n\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.\nShe noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"\nGiven the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. Investors and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.\nWASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images\nIn September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"\nWhile the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least one hike.\n\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, Charles Schwab chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"\nOctober jobs report\nOne of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.\nEconomists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.\nStill, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.\nOne factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.\n\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.\nBut some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.\nEconomic calendar\n\nMonday: Markit U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)\nTuesday: No notable reports scheduled for release\nWednesday: MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision\nThursday: Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in Q2); Unit Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)\nFriday: Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)\n\nEarnings calendar\n\nMonday: Clorox (CLX), Avis Budget Group (CAR), ZoomInfo Technologies (ZI), Chegg Inc. (CHGG), Diamondback Energy (FANG), The Simon Property Group (SPG) after market close\nTuesday: Under Armour (UAA), Estee Lauder (EL), Ralph Lauren (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), Bloomin' Brands (BLMN), ConocoPhillips (COP), Pfizer (PFE), Groupon (GPN), Marathon Petroleum (MPC) before market open; Mondelez (MDLZ), T-Mobile (TMUS), Akamai (AKAM), Activision Blizzard (ATVI), Lyft (LYFT), Match Group (MTCH), Devon Energy (DVN), Chesapeake Energy (CHK), Coursera (COUR), Zillow Group (ZG), Amgen (AMGN) after market close\nWednesday: Humana (HUM), Discovery Inc. (DISCA), The New York Times (NYT), Norwegian Cruise Line Holdings (NCLH), Marriott International (MAR), CVS Health Corp. (CVS), Sinclair Broadcast Group (SBGI) before market open; Booking Holdings (BKNG), Qorvo (QRVO), The Allstate Corp. (ALL), MGM Resorts International (MGM), $Take-Two Interactive Software(TTWO)$ (TTWO), Electronic Arts (EA), Vimeo (VMEO), Etsy (ETSY), GoDaddy (GDDY), Marathon Oil Corp. (MRO), Roku (ROKU), Qualcomm (QCOM) after market close\nThursday: Cigna (CI), Wayfair (W), ViacomCBS (VIAC), Nikola (NKLA), Duke Energy (DUK), Citrix Systems (CTXS), Regeneron Pharmaceuticals (REGN), Hanesbrands (HBI), Moderna (MRNA), Planet Fitness (PLNT), Vulcan Material (VMC), Kellogg (K), Square (SQ), Cloudflare (NET), Occidental Petroleum (OXY), Uber Technologies (UBER), American International Group (AIG), Shake Shack (SHAK), iHeartMedia (IHRT), Novavax (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), Skyworks Solutions (SWKS), Expedia (EXPE), Rocket Cos. (RKT), Live Nation Entertainment (LYV), Airbnb (ABNB)\nFriday: Wynn Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), Goodyear Tire and Rubber (GT), Cinemark Holdings (CNK) before market open","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,"UBER":0.9,"ATVI":0.9,"CLX":0.9,"BLMN":0.9,"COP":0.9,"PFE":0.9,"APO":0.9,"EL":0.9,".IXIC":0.9,"CRSR":0.9,"RL":0.9}},"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690874632,"gmtCreate":1639659855187,"gmtModify":1639659855348,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay 👌&nbsp;","listText":"Okay 👌&nbsp;","text":"Okay 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690874632","repostId":"1142996286","repostType":4,"repost":{"id":"1142996286","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639659703,"share":"https://www.laohu8.com/m/news/1142996286?lang=zh_CN&edition=full","pubTime":"2021-12-16 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142996286","media":"Tiger Newspress","summary":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.$Delta Air Lines$ – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-","content":"<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p><p><blockquote>美国股指期货周四上午上涨，此前市场在前一交易日出现180度大转弯，欢迎美联储决定加快缩减规模并暂时维持利率不变。</blockquote></p><p> At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨204点，涨幅0.57%，标普500 e-mini上涨31.25点，涨幅0.66%，纳斯达克100 e-mini上涨115.25点，涨幅0.71%。随着美联储周三给市场喘息的机会，交易员将在周四转向劳工部关于每周首次申请失业救济人数的最新数据。首次申请失业救济人数预计将在去年创下52周低点后小幅上升。</blockquote></p><p> <b>Stocks making the biggest moves premarket: </b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p><p><blockquote><b><a href=\"https://laohu8.com/S/DAL\">达美航空</a></b>-达美航空预计第四季度利润为2亿美元，盘前上涨2.3%。市场普遍预测达美航空将出现季度亏损，但该航空公司表示，假期需求强劲，利润有望超过大流行前的水平。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ACN\">埃森哲公司</a></b>-该咨询公司公布最新季度利润和收入好于预期，并上调2022财年盈利指引后，其股价盘前飙升6.7%。埃森哲客户群中四个最大行业集团的收入增长了20%以上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p><p><blockquote><b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>-该制药商表示其抗体鸡尾酒对奥密克戎Covid-19变种失去效力后，其股价在盘前交易中下跌1%。再生元确实说过这种鸡尾酒对德尔塔变异毒株有效。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p><p><blockquote><b><a href=\"https://laohu8.com/S/LEN\">伦纳尔</a></b>-Lennar公布的季度收益为每股3.91美元，低于市场普遍预期的4.15美元，该住宅建筑商的收入也低于预期。Lennar受到木材成本上涨、劳动力成本增加和原材料短缺的影响，导致送货上门延迟。Lennar在盘前下跌6.3%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/NVS\">诺华公司</a></b>-诺华启动了一项价值高达150亿美元的新股票回购计划，该制药商计划在2023年底前完成这些回购。股价在盘前交易中上涨4%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p><p><blockquote><b><a href=\"https://laohu8.com/S/V\">签证</a> </b>–<a href=\"https://laohu8.com/S/V\">签证</a>盘前股价上涨1.1%，此前该公司宣布向其股票回购计划增加120亿美元，使其回购授权总额达到132亿美元。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SJM\">Smucker的</a></b>-Smucker达成协议，以1.1亿美元的价格将其天然饮料和谷物业务出售给私募股权公司Nexus Capital Management，这家食品生产商表示希望将更多资源集中在其核心品牌上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ISRG\">直观手术</a></b>–<a href=\"https://laohu8.com/S/ISRG\">直观手术</a>被添加到高盛的“坚定买入”名单中，这表明该公司即将推出一种新的手术系统。盘前股价上涨1.2%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/T\">AT&amp;T公司</a></b>-摩根士丹利将AT&amp;T的评级从“同等权重”上调至“跑赢大盘”，称该股近期的下滑创造了有吸引力的风险回报状况。该公司表示，还有其他几个关键因素推动了此次升级，包括WarnerMedia/Discovery合并即将完成。AT&amp;T在盘前交易中上涨1.5%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p><p><blockquote><b><a href=\"https://laohu8.com/S/WOOF\">Petco健康和保健公司。</a></b>-在Needham开始给予“买入”评级后，这家宠物产品销售商的股价在盘前上涨了1.9%。该公司认为，鉴于Petco在包括兽医医院在内的多个渠道中的存在，它应该会超越宠物类别的竞争对手。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>–Evercore将其评级从“持平”上调至“跑赢大盘”后，该电子商务平台运营商在盘前交易中上涨2.9%。Evercore指出，该股比年度高点低约20%，就增长机会而言，该公司代表着优质资产。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-16 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p><p><blockquote>美国股指期货周四上午上涨，此前市场在前一交易日出现180度大转弯，欢迎美联储决定加快缩减规模并暂时维持利率不变。</blockquote></p><p> At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨204点，涨幅0.57%，标普500 e-mini上涨31.25点，涨幅0.66%，纳斯达克100 e-mini上涨115.25点，涨幅0.71%。随着美联储周三给市场喘息的机会，交易员将在周四转向劳工部关于每周首次申请失业救济人数的最新数据。首次申请失业救济人数预计将在去年创下52周低点后小幅上升。</blockquote></p><p> <b>Stocks making the biggest moves premarket: </b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p><p><blockquote><b><a href=\"https://laohu8.com/S/DAL\">达美航空</a></b>-达美航空预计第四季度利润为2亿美元，盘前上涨2.3%。市场普遍预测达美航空将出现季度亏损，但该航空公司表示，假期需求强劲，利润有望超过大流行前的水平。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ACN\">埃森哲公司</a></b>-该咨询公司公布最新季度利润和收入好于预期，并上调2022财年盈利指引后，其股价盘前飙升6.7%。埃森哲客户群中四个最大行业集团的收入增长了20%以上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p><p><blockquote><b><a href=\"https://laohu8.com/S/REGN\">再生元制药</a></b>-该制药商表示其抗体鸡尾酒对奥密克戎Covid-19变种失去效力后，其股价在盘前交易中下跌1%。再生元确实说过这种鸡尾酒对德尔塔变异毒株有效。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p><p><blockquote><b><a href=\"https://laohu8.com/S/LEN\">伦纳尔</a></b>-Lennar公布的季度收益为每股3.91美元，低于市场普遍预期的4.15美元，该住宅建筑商的收入也低于预期。Lennar受到木材成本上涨、劳动力成本增加和原材料短缺的影响，导致送货上门延迟。Lennar在盘前下跌6.3%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/NVS\">诺华公司</a></b>-诺华启动了一项价值高达150亿美元的新股票回购计划，该制药商计划在2023年底前完成这些回购。股价在盘前交易中上涨4%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p><p><blockquote><b><a href=\"https://laohu8.com/S/V\">签证</a> </b>–<a href=\"https://laohu8.com/S/V\">签证</a>盘前股价上涨1.1%，此前该公司宣布向其股票回购计划增加120亿美元，使其回购授权总额达到132亿美元。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SJM\">Smucker的</a></b>-Smucker达成协议，以1.1亿美元的价格将其天然饮料和谷物业务出售给私募股权公司Nexus Capital Management，这家食品生产商表示希望将更多资源集中在其核心品牌上。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ISRG\">直观手术</a></b>–<a href=\"https://laohu8.com/S/ISRG\">直观手术</a>被添加到高盛的“坚定买入”名单中，这表明该公司即将推出一种新的手术系统。盘前股价上涨1.2%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p><p><blockquote><b><a href=\"https://laohu8.com/S/T\">AT&amp;T公司</a></b>-摩根士丹利将AT&amp;T的评级从“同等权重”上调至“跑赢大盘”，称该股近期的下滑创造了有吸引力的风险回报状况。该公司表示，还有其他几个关键因素推动了此次升级，包括WarnerMedia/Discovery合并即将完成。AT&amp;T在盘前交易中上涨1.5%。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p><p><blockquote><b><a href=\"https://laohu8.com/S/WOOF\">Petco健康和保健公司。</a></b>-在Needham开始给予“买入”评级后，这家宠物产品销售商的股价在盘前上涨了1.9%。该公司认为，鉴于Petco在包括兽医医院在内的多个渠道中的存在，它应该会超越宠物类别的竞争对手。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p><p><blockquote><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>–Evercore将其评级从“持平”上调至“跑赢大盘”后，该电子商务平台运营商在盘前交易中上涨2.9%。Evercore指出，该股比年度高点低约20%，就增长机会而言，该公司代表着优质资产。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142996286","content_text":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.\nAt 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.With the Fed giving markets a breather Wednesday, traders will turn their Thursday to fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after last’s 52-week low.\nStocks making the biggest moves premarket: \nDelta Air Lines – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.\nAccenture PLC – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.\nRegeneron Pharmaceuticals – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.\nLennar – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.\nNovartis AG – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.\nVisa – Visa rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.\nSmucker's – Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.\nIntuitive Surgical – Intuitive Surgical was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.\nAT&T Inc – Morgan Stanley upgraded AT&T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&T gained 1.5% in premarket trading.\nPetco Health and Wellness Company, Inc. – The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.\nShopify – The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":4502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872777574,"gmtCreate":1637582901485,"gmtModify":1637582901485,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872777574","repostId":"1171692239","repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-22 20:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京11月22日-中国科技巨头百度公司(9888.HK)周一表示，已将其信使RNA(mRNA)序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其首个此类产品。与全球主要制药商达成商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲(SASY.PA)在大流行之前一直是世界上最大的疫苗制造商之一，但这家法国公司在开发针对COVID-19的mRNA疫苗方面被竞争对手BioNTech/辉瑞(PFE.N)和Moderna(MRNA.O)击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于9月停止了自己的mRNA COVID-19疫苗的试验，转而专注于与葛兰素史克(GSK.L)合作，将另一种基于更传统的蛋白质方法的COVID-19候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>这家法国集团表示，它将把其mRNA资源集中用于其他需求未得到满足的传染病和治疗方法。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>“这项协议包括里程碑付款的事实表明，[赛诺菲]非常有信心将使用百度算法开发的候选药物带入临床试验并推向市场，”Huang告诉路透社。他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人类细胞产生可以刺激免疫系统发挥作用的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供大量优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>特别是关于COVID-19候选疫苗，根据尚未通过的实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎比基于标准算法的基线注射需要更小的剂量。同行评审。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09888":"百度集团-SW","SNYNF":"Sanofi","BIDU":"百度"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"SNYNF":0.9,"09888":0.9,"BIDU":0.9}},"isVote":1,"tweetType":1,"viewCount":9300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841634688,"gmtCreate":1635905542092,"gmtModify":1635905542092,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841634688","repostId":"2180736486","repostType":4,"isVote":1,"tweetType":1,"viewCount":1123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608178636,"gmtCreate":1638672598165,"gmtModify":1638672598165,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608178636","repostId":"2188057871","repostType":4,"isVote":1,"tweetType":1,"viewCount":3327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878532155,"gmtCreate":1637204802922,"gmtModify":1637204802922,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878532155","repostId":"1161909759","repostType":4,"repost":{"id":"1161909759","kind":"news","pubTimestamp":1637203262,"share":"https://www.laohu8.com/m/news/1161909759?lang=zh_CN&edition=full","pubTime":"2021-11-18 10:41","market":"us","language":"en","title":"Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161909759","media":"The Street","summary":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences","content":"<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.</p><p><blockquote>该生物技术公司面临操纵其阿尔茨海默氏症药物研究结果的指控。</blockquote></p><p> $Cassava Sciences&nbsp;(<b>SAVA</b>)$&nbsp;plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included&nbsp;the Securities and Exchange Commission, were investing claims the biotech&nbsp;manipulated research results of its experimental Alzheimer’s drug,&nbsp;simufilam.</p><p><blockquote>$木薯科学(<b>萨瓦</b>)周三，在披露“某些政府机构”（据报道包括美国证券交易委员会）正在投资声称该生物技术公司操纵其实验性阿尔茨海默病药物simufilam的研究结果后，美元暴跌。</blockquote></p><p> Shares of the Austin, Texas company were&nbsp;down more&nbsp;than 23% to $47.07&nbsp;Wednesday.</p><p><blockquote>周三，这家位于德克萨斯州奥斯汀的公司股价下跌超过23%，至47.07美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ba12f81714da2c89bed996a8439c131d\" tg-width=\"882\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.</p><p><blockquote>Cassava在一份证券文件中表示，“某些政府机构要求我们向他们提供公司信息和文件”，《华尔街日报》援引知情人士的话称，该机构是SEC。</blockquote></p><p> \"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"</p><p><blockquote>Cassava表示：“我们一直在并将继续与政府当局合作。”“没有任何政府机构通知我们任何一方有任何不当行为。”</blockquote></p><p> The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.</p><p><blockquote>据该公司首席执行官称，美国国立卫生研究院自2015年以来向Cassava及其学术合作者提供了2000万美元的药物开发资助，该公司也在审查这些说法。</blockquote></p><p> Cassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to&nbsp;halt to trials of simufilam.</p><p><blockquote>今年8月，Labaton Sucharow举报人代理业务的合伙人兼主席乔丹·托马斯(Jordan Thomas)向美国提交了一份公民请愿书，木薯科学公司卷入了争议。食品药品监督管理局试图停止simufilam的试验。</blockquote></p><p> On Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"</p><p><blockquote>周三，托马斯给代理美国国务卿写了一封信。美国食品和药物管理局珍妮特·伍德库克(Janet Woodcock)表示：“我的客户对Cassava Sciences最担心的事情似乎是真的。”</blockquote></p><p> Thomas identified his clients as&nbsp;David Bredt, former neuroscience research chief at Johnson &amp; Johnson&nbsp;(<b>JNJ</b>) Report&nbsp;and Eli Lilly &amp; Co.&nbsp;(<b>LLY</b>) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine</p><p><blockquote>托马斯确认他的客户是强生公司前神经科学研究主管大卫·布雷特（David Bredt）（<b>JNJ</b>）报告和礼来公司（<b>LLY</b>），以及威尔康奈尔医学院心脏病专家兼教授杰弗里·皮特</blockquote></p><p> \"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"</p><p><blockquote>托马斯说：“由于他们对simufilam和Cassava的相关研究的严重担忧，并冒着巨大的个人和职业风险，我的举报人客户以及其他著名的医生和科学家自愿公开了此事。”</blockquote></p><p> Bredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.</p><p><blockquote>Bredt和Pitt写道，Cassava的研究包括实验图像，这些图像似乎是使用Photoshop等软件操纵的。</blockquote></p><p> Thomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"</p><p><blockquote>托马斯说，“越来越多的证据表明，Cassava篡改了其研究和临床试验结果，欺骗了同行评审期刊，利用受污染的科学欺骗NIH和FDA批准拨款和临床试验。”</blockquote></p><p> In addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"</p><p><blockquote>此外，该公司“通过兜售其资助和临床试验而不披露其令人不安的研究实践来误导投资者，并向脆弱的阿尔茨海默病患者隐瞒有关其药物真实性质的重要信息。”</blockquote></p><p> The FDA has a duty, Thomas said,&nbsp;\"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"</p><p><blockquote>Thomas表示，FDA有责任“立即停止simufilam临床试验，对该公司的所有研究和临床试验结果进行严格审核，并向感兴趣的执法和监管机构报告该机构的调查结果。”</blockquote></p><p> Cassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.</p><p><blockquote>Cassava没有立即回应置评请求，但首席执行官雷米·栗林诚一郎表示，卖空者滥用了FDA的请愿程序。</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Street</strong><span class=\"h-time small\">2021-11-18 10:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.</p><p><blockquote>该生物技术公司面临操纵其阿尔茨海默氏症药物研究结果的指控。</blockquote></p><p> $Cassava Sciences&nbsp;(<b>SAVA</b>)$&nbsp;plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included&nbsp;the Securities and Exchange Commission, were investing claims the biotech&nbsp;manipulated research results of its experimental Alzheimer’s drug,&nbsp;simufilam.</p><p><blockquote>$木薯科学(<b>萨瓦</b>)周三，在披露“某些政府机构”（据报道包括美国证券交易委员会）正在投资声称该生物技术公司操纵其实验性阿尔茨海默病药物simufilam的研究结果后，美元暴跌。</blockquote></p><p> Shares of the Austin, Texas company were&nbsp;down more&nbsp;than 23% to $47.07&nbsp;Wednesday.</p><p><blockquote>周三，这家位于德克萨斯州奥斯汀的公司股价下跌超过23%，至47.07美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ba12f81714da2c89bed996a8439c131d\" tg-width=\"882\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.</p><p><blockquote>Cassava在一份证券文件中表示，“某些政府机构要求我们向他们提供公司信息和文件”，《华尔街日报》援引知情人士的话称，该机构是SEC。</blockquote></p><p> \"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"</p><p><blockquote>Cassava表示：“我们一直在并将继续与政府当局合作。”“没有任何政府机构通知我们任何一方有任何不当行为。”</blockquote></p><p> The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.</p><p><blockquote>据该公司首席执行官称，美国国立卫生研究院自2015年以来向Cassava及其学术合作者提供了2000万美元的药物开发资助，该公司也在审查这些说法。</blockquote></p><p> Cassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to&nbsp;halt to trials of simufilam.</p><p><blockquote>今年8月，Labaton Sucharow举报人代理业务的合伙人兼主席乔丹·托马斯(Jordan Thomas)向美国提交了一份公民请愿书，木薯科学公司卷入了争议。食品药品监督管理局试图停止simufilam的试验。</blockquote></p><p> On Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"</p><p><blockquote>周三，托马斯给代理美国国务卿写了一封信。美国食品和药物管理局珍妮特·伍德库克(Janet Woodcock)表示：“我的客户对Cassava Sciences最担心的事情似乎是真的。”</blockquote></p><p> Thomas identified his clients as&nbsp;David Bredt, former neuroscience research chief at Johnson &amp; Johnson&nbsp;(<b>JNJ</b>) Report&nbsp;and Eli Lilly &amp; Co.&nbsp;(<b>LLY</b>) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine</p><p><blockquote>托马斯确认他的客户是强生公司前神经科学研究主管大卫·布雷特（David Bredt）（<b>JNJ</b>）报告和礼来公司（<b>LLY</b>），以及威尔康奈尔医学院心脏病专家兼教授杰弗里·皮特</blockquote></p><p> \"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"</p><p><blockquote>托马斯说：“由于他们对simufilam和Cassava的相关研究的严重担忧，并冒着巨大的个人和职业风险，我的举报人客户以及其他著名的医生和科学家自愿公开了此事。”</blockquote></p><p> Bredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.</p><p><blockquote>Bredt和Pitt写道，Cassava的研究包括实验图像，这些图像似乎是使用Photoshop等软件操纵的。</blockquote></p><p> Thomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"</p><p><blockquote>托马斯说，“越来越多的证据表明，Cassava篡改了其研究和临床试验结果，欺骗了同行评审期刊，利用受污染的科学欺骗NIH和FDA批准拨款和临床试验。”</blockquote></p><p> In addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"</p><p><blockquote>此外，该公司“通过兜售其资助和临床试验而不披露其令人不安的研究实践来误导投资者，并向脆弱的阿尔茨海默病患者隐瞒有关其药物真实性质的重要信息。”</blockquote></p><p> The FDA has a duty, Thomas said,&nbsp;\"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"</p><p><blockquote>Thomas表示，FDA有责任“立即停止simufilam临床试验，对该公司的所有研究和临床试验结果进行严格审核，并向感兴趣的执法和监管机构报告该机构的调查结果。”</blockquote></p><p> Cassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.</p><p><blockquote>Cassava没有立即回应置评请求，但首席执行官雷米·栗林诚一郎表示，卖空者滥用了FDA的请愿程序。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation\">The Street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161909759","content_text":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences (SAVA)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.\nShares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.\n\nCassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.\n\"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"\nThe National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.\nCassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.\nOn Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"\nThomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (JNJ) Report and Eli Lilly & Co. (LLY) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine\n\"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"\nBredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.\nThomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"\nIn addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"\nThe FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"\nCassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.","news_type":1,"symbols_score_info":{"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":1503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841619557,"gmtCreate":1635905743400,"gmtModify":1635905743400,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841619557","repostId":"1186977790","repostType":4,"isVote":1,"tweetType":1,"viewCount":1346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849836891,"gmtCreate":1635740774157,"gmtModify":1635740774157,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849836891","repostId":"1164035523","repostType":4,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MREO":"Mereo Biopharma Group Plc","SENS":"Senseonics Holdings,Inc."},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"MREO":0.9,"SENS":0.9}},"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874953784,"gmtCreate":1637722659359,"gmtModify":1637722659423,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874953784","repostId":"1178572049","repostType":4,"isVote":1,"tweetType":1,"viewCount":3823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847463409,"gmtCreate":1636546529729,"gmtModify":1636546529907,"author":{"id":"4094912318336650","authorId":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094912318336650","authorIdStr":"4094912318336650"},"themes":[],"htmlText":"Okay 👌&nbsp;","listText":"Okay 👌&nbsp;","text":"Okay 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847463409","repostId":"1153527139","repostType":4,"isVote":1,"tweetType":1,"viewCount":875,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}